RepliCel Historical Financial Ratios
| RP Stock | CAD 0.01 0.00 0.00% |
RepliCel Life is promptly reporting on over 87 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Average Payables of 274.5 K, Stock Based Compensation To Revenue of 0.72, Capex To Depreciation of 0.0022 or Ev To Sales of 20.41 will help investors to properly organize and evaluate RepliCel Life Sciences financial condition quickly.
RepliCel |
About RepliCel Financial Ratios Analysis
RepliCel Life SciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate RepliCel Life investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on RepliCel financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across RepliCel Life history.
RepliCel Life Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing RepliCel Life Sciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on RepliCel Life sales, a figure that is much harder to manipulate than other RepliCel Life Sciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from RepliCel Life's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into RepliCel Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RepliCel Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, RepliCel Life's Invested Capital is fairly stable compared to the past year. Stock Based Compensation To Revenue is likely to climb to 0.72 in 2024, despite the fact that PTB Ratio is likely to grow to (0.81).
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 0.77 | 0.26 | 0.0952 | 0.0904 | Receivables Turnover | 5.78 | 4.3 | 10.0 | 9.5 |
RepliCel Life fundamentals Correlations
Click cells to compare fundamentals
RepliCel Life Account Relationship Matchups
High Positive Relationship
High Negative Relationship
RepliCel Life fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 17.38 | 17.53 | 21.12 | 9.08 | 10.89 | 10.34 | |
| Ptb Ratio | (1.39) | (1.23) | (1.09) | (0.54) | (0.85) | (0.81) | |
| Days Sales Outstanding | 53.55 | 65.64 | 63.19 | 84.79 | 36.5 | 34.68 | |
| Book Value Per Share | (0.18) | (0.19) | (0.21) | (0.16) | (0.0765) | (0.0803) | |
| Free Cash Flow Yield | (0.45) | (0.12) | (0.34) | (0.44) | (0.37) | (0.39) | |
| Operating Cash Flow Per Share | (0.12) | (0.0284) | (0.0774) | (0.0373) | (0.0239) | (0.0251) | |
| Average Payables | 595.7K | 848.5K | 829.4K | 709.9K | 482.9K | 274.5K | |
| Pb Ratio | (1.39) | (1.23) | (1.09) | (0.54) | (0.85) | (0.81) | |
| Ev To Sales | 18.58 | 17.65 | 20.59 | 8.02 | 13.19 | 20.41 | |
| Free Cash Flow Per Share | (0.12) | (0.0284) | (0.0774) | (0.0373) | (0.0239) | (0.0251) | |
| Roic | 6.02 | 0.74 | 0.29 | 0.4 | 0.0969 | 0.38 | |
| Net Income Per Share | (0.13) | (0.12) | (0.0586) | (0.0197) | (0.005262) | (0.005525) | |
| Sales General And Administrative To Revenue | 3.07 | 2.5 | 4.26 | 3.18 | 3.43 | 5.46 | |
| Research And Ddevelopement To Revenue | 6.21 | 2.32 | 3.25 | 1.76 | 1.49 | 1.41 | |
| Cash Per Share | 0.002185 | 0.001914 | 0.00734 | 0.0114 | 0.00129 | 0.001225 | |
| Pocfratio | (2.21) | (8.1) | (2.97) | (2.28) | (2.72) | (2.86) | |
| Pfcf Ratio | (2.21) | (8.1) | (2.97) | (2.28) | (2.72) | (2.86) | |
| Income Quality | 0.93 | 0.48 | 0.62 | 1.9 | 4.54 | 4.76 | |
| Roe | 0.68 | 0.31 | 0.6 | 0.13 | 0.0688 | 0.0722 | |
| Ev To Operating Cash Flow | (2.36) | (8.16) | (2.9) | (2.01) | (3.3) | (3.46) | |
| Pe Ratio | (2.05) | (3.92) | (1.83) | (4.32) | (12.35) | (12.97) | |
| Return On Tangible Assets | (5.94) | (3.75) | (6.88) | (0.93) | (1.08) | (1.14) | |
| Ev To Free Cash Flow | (2.36) | (8.16) | (2.9) | (2.01) | (3.3) | (3.46) | |
| Earnings Yield | (0.49) | (0.25) | (0.55) | (0.23) | (0.081) | (0.085) | |
| Net Debt To E B I T D A | (0.14) | (0.0276) | 0.0476 | 0.56 | (0.59) | (0.62) | |
| Current Ratio | 0.15 | 0.0829 | 0.23 | 0.31 | 0.0889 | 0.0845 | |
| Tangible Book Value Per Share | (0.18) | (0.19) | (0.21) | (0.16) | (0.0765) | (0.0803) | |
| Receivables Turnover | 6.82 | 5.56 | 5.78 | 4.3 | 10.0 | 9.5 | |
| Graham Number | 0.72 | 0.5 | 0.77 | 0.26 | 0.0952 | 0.0904 | |
| Shareholders Equity Per Share | (0.18) | (0.19) | (0.21) | (0.16) | (0.0765) | (0.0803) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RepliCel Stock Analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.